Last reviewed · How we verify
Influenza A Virus
This is not a drug but a pathogenic virus; Merck manufactures vaccines and antivirals against Influenza A Virus.
This is not a drug but a pathogenic virus; Merck manufactures vaccines and antivirals against Influenza A Virus. Used for Prevention of seasonal influenza A infection, Treatment of acute influenza A infection.
At a glance
| Generic name | Influenza A Virus |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Influenza A Virus is the causative agent of seasonal and pandemic influenza. Merck's marketed products against this virus include inactivated influenza vaccines (e.g., Fluzone) that stimulate immune responses, and antivirals like oseltamivir (Tamiflu) that inhibit viral neuraminidase to prevent viral release from infected cells. These interventions either prevent infection or reduce viral replication and symptom severity.
Approved indications
- Prevention of seasonal influenza A infection
- Treatment of acute influenza A infection
Common side effects
- Injection site reactions (pain, redness, swelling)
- Myalgia
- Headache
- Fever
- Nausea (antivirals)
Key clinical trials
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (PHASE3)
- Influenza Human Challenge Model (PHASE1)
- A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above (PHASE2)
- Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 Influenza (PHASE1)
- BPL-1357 Against H1N1 Influenza Virus Challenge (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- RSV Burden in Outpatient and Hospital Settings (NA)
- Nasopharyngeal Carriage of S. Pneumoniae (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza A Virus CI brief — competitive landscape report
- Influenza A Virus updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI